


23 de octubre de 2024

## Anti-BAMBI mAb: Towards a new novel disruptive therapy in psoriasis and psoriatic arthritis




***Ramón Merino, MD, PhD***  
***Scientific advisor & co-founder***



MEDICAMENTOS INNOVADORES  
Plataforma Tecnológica Española





## Inhibitec Anticuerpos SL



## Our product: anti-BAMBI mAb (B101.37)

Inhibitec has identified **BAMBI** as a key molecule during PsA development and produced an inhibitory mAb (B101.37)



Anti-BAMBI mAb (IgG1)  
recognizes both murine and human BAMBI

## Target indications

Psoriasis is an autoimmune disease of the skin that affects about 2% of the global population (≈ 160 million of patients). According to WHO: Chronic, noncommunicable, painful, disfiguring and disabling with **no cure**.



**Prevalence (%) of psoriasis by sex:**



30% of patients with psoriasis will develop **Psoriatic Arthritis (PsA)**




Higher economic burden when including **comorbidities** (30-194% increase).

**Prevalence rise.** It will double in the next 5 years.



## Innovative mechanisms of action

$\alpha$ -Bambi treatment has double effect on psoriasis and PsA: It **enhances Treg** differentiation **AND inhibits pro-inflammatory cells**.





## Innovative mechanisms of action




**Inhibiting BAMBI prevents skin lesions and joint thickening during PsA progression**

### IPR protection

- Anti-BAMBI mAb has been protected by an International Patent filed in November 2015 ***‘Anticuerpos monoclonales frente a BAMBI y uso para tratamiento de enfermedades inflamatorias’*** (EU ref number EP3385282; US patent ref 11,518,802) and it is valid to 2035 (+5-year extension)
- Ownership is evenly split between the Spanish National Research Council (CSIC) (50%) and the University of Cantabria (UC) (50%), with a co-ownership agreement fully executed.
- Our patent covers the therapeutic applications of psoriasis, psoriatic arthritis, rheumatoid arthritis, systemic lupus erythematosus (SLE) and IBDs such as ulcerative colitis.
- Inhibitec is proactively pursuing a robust and ambitious plan to strengthen and extend our intellectual property portfolio, potentially resulting in a new patent of the humanized anti-BAMBI mAb.


## Target indications: complete portfolio

### Therapeutic applications



**\$3.3 B**  
Lupus market


### Diagnostic applications



**\$6.6 B**  
Ulcerative colitis  
market



### Current status of development



## XXIV Encuentro de Cooperación Farma-Biotech

### Differentiation

Competitors today  
Partners tomorrow

<b>COMPANY</b>	Several companies Abbvie	Novartis Lilly Leo Pharma UBC	Janssen Almirall Janssen	Inhibitec
<b>NAME</b>	<i>Adalimumab</i>	<i>Secukimumab</i> <i>Ixekizumab</i> <i>Brodalumab</i> <i>Bimekizumab</i>	<i>Ustekinumab</i> <i>Tildrakizumab</i> <i>Guselkumab</i>	<i>Anti-BAMBI</i>
<b>TARGET</b>	TNFa	IL-17A IL-17RA IL17A/IL17F	anti-IL-23p40 IL-23p19	BAMBI

<b>Options in the market</b>	Multiple	Multiple	Multiple	<b>Only Inhibitec</b>
<b>Patent lifespan</b>	Biosimilars	Close to expire	Close to expire	<b>Newer</b>
<b>Dual cellular effect</b>	-	-	-	✓
<b>Effect on psoriasis</b>	+++	+++	+++	++++
<b>Effect on PsA</b>	++	++	++	++++

### Pitfalls & Risk

**Comparative therapeutic effects:** Treatment with hB101.37 mAb does not improve the therapeutic landscape in these pathologies.

- *hB101.37 therapy has broader therapeutic effects than anti-IL-17 mAbs in psoriasis models.*

**Toxicity:** The pre-clinical roadmap for hB101.37 mAb will be interrupted in the case of severe side effects to its treatment.

- *No toxicity in both acute and chronic administration regimens.*
- *No profibrotic side effects in experimental models of lung, heart, liver, and skin fibrosis*
- *No haemorrhagic side effects.*

**Stable cell line production:** Producing the hB101.37 mAb by the stable cell line may suffer modifications that affect their therapeutic effect or have a large-scale failure that compromise the productivity.

- *A comprehensive sequence analysis of hB101.37 performed to enhance stability and efficiency during cell line production.*

### Partnering opportunities





**Investment**



**Co-development**



**Licensing**



**Research collaborations**